0001209191-23-034389.txt : 20230605 0001209191-23-034389.hdr.sgml : 20230605 20230605164724 ACCESSION NUMBER: 0001209191-23-034389 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230601 FILED AS OF DATE: 20230605 DATE AS OF CHANGE: 20230605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Carey Robert CENTRAL INDEX KEY: 0001602064 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-30171 FILM NUMBER: 23993271 MAIL ADDRESS: STREET 1: HORIZON PHARMA, INC. STREET 2: 520 LAKE COOK ROAD, SUITE 520 CITY: DEERFIELD STATE: IL ZIP: 60062 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC CENTRAL INDEX KEY: 0001001233 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 680359556 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 5109706000 MAIL ADDRESS: STREET 1: 7000 MARINA BLVD CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC DATE OF NAME CHANGE: 20000208 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-06-01 0 0001001233 SANGAMO THERAPEUTICS, INC SGMO 0001602064 Carey Robert C/O SANGAMO THERAPEUTICS, INC. 7000 MARINA BLVD. BRISBANE CA 94005 1 0 0 0 0 Common Stock 2023-06-01 4 A 0 13900 0.00 A 49600 D Stock Option (Right to Buy) 1.11 2023-06-01 4 A 0 27750 0.00 A 2033-05-31 Common Stock 27750 27750 D Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will fully vest on the earlier of (a) June 1, 2024 or (b) the day prior to the 2024 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Robert F. Carey, by /s/ Ron A. Metzger, Attorney-in-Fact 2023-06-05